Table of Content

1. Product Overview
2. Research Methodology
3. Executive Summary
4. Impact of COVID-19 on Global Hematologic Malignancies Testing Market
5. Voice of Customer
6. Clinical Trial Analysis
7. Global Hematologic Malignancies Testing Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Component (Kits v/s Services)
7.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
7.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
7.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
7.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
7.2.5. By Company (2021)
7.2.6. By Region
7.3. Market Map
8. North America Hematologic Malignancies Testing Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Component (Kits v/s Services)
8.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
8.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
8.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
8.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
8.2.5. By Country
8.3. North America: Country Analysis
8.3.1. United States Hematologic Malignancies Testing Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Component
8.3.1.2.2. By Technique
8.3.1.2.3. By Therapeutic Indication
8.3.1.2.4. By End User
8.3.2. Canada Hematologic Malignancies Testing Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Component
8.3.2.2.2. By Technique
8.3.2.2.3. By Therapeutic Indication
8.3.2.2.4. By End User
8.3.3. Mexico Hematologic Malignancies Testing Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Component
8.3.3.2.2. By Technique
8.3.3.2.3. By Therapeutic Indication
8.3.3.2.4. By End User
9. Europe Hematologic Malignancies Testing Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Component (Kits v/s Services)
9.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
9.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
9.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
9.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
9.2.5. By Country
9.3. Europe: Country Analysis
9.3.1. France Hematologic Malignancies Testing Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Component
9.3.1.2.2. By Technique
9.3.1.2.3. By Therapeutic Indication
9.3.1.2.4. By End User
9.3.2. Germany Hematologic Malignancies Testing Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Component
9.3.2.2.2. By Technique
9.3.2.2.3. By Therapeutic Indication
9.3.2.2.4. By End User
9.3.3. United Kingdom Hematologic Malignancies Testing Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Component
9.3.3.2.2. By Technique
9.3.3.2.3. By Therapeutic Indication
9.3.3.2.4. By End User
9.3.4. Italy Hematologic Malignancies Testing Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Component
9.3.4.2.2. By Technique
9.3.4.2.3. By Therapeutic Indication
9.3.4.2.4. By End User
9.3.5. Spain Hematologic Malignancies Testing Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Component
9.3.5.2.2. By Technique
9.3.5.2.3. By Therapeutic Indication
9.3.5.2.4. By End User
10. Asia-Pacific Hematologic Malignancies Testing Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Component (Kits v/s Services)
10.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
10.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
10.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
10.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
10.2.5. By Country
10.3. Asia-Pacific: Country Analysis
10.3.1. China Hematologic Malignancies Testing Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Component
10.3.1.2.2. By Technique
10.3.1.2.3. By Therapeutic Indication
10.3.1.2.4. By End User
10.3.2. India Hematologic Malignancies Testing Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Component
10.3.2.2.2. By Technique
10.3.2.2.3. By Therapeutic Indication
10.3.2.2.4. By End User
10.3.3. Japan Hematologic Malignancies Testing Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Component
10.3.3.2.2. By Technique
10.3.3.2.3. By Therapeutic Indication
10.3.3.2.4. By End User
10.3.4. South Korea Hematologic Malignancies Testing Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Component
10.3.4.2.2. By Technique
10.3.4.2.3. By Therapeutic Indication
10.3.4.2.4. By End User
10.3.5. Australia Hematologic Malignancies Testing Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Component
10.3.5.2.2. By Technique
10.3.5.2.3. By Therapeutic Indication
10.3.5.2.4. By End User
11. South America Hematologic Malignancies Testing Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Component (Kits v/s Services)
11.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
11.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
11.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
11.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
11.2.5. By Country
11.3. South America: Country Analysis
11.3.1. Brazil Hematologic Malignancies Testing Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Component
11.3.1.2.2. By Technique
11.3.1.2.3. By Therapeutic Indication
11.3.1.2.4. By End User
11.3.2. Argentina Hematologic Malignancies Testing Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Component
11.3.2.2.2. By Technique
11.3.2.2.3. By Therapeutic Indication
11.3.2.2.4. By End User
11.3.3. Colombia Hematologic Malignancies Testing Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Component
11.3.3.2.2. By Technique
11.3.3.2.3. By Therapeutic Indication
11.3.3.2.4. By End User
12. Middle East and Africa Hematologic Malignancies Testing Market Outlook
12.1. Market Size & Forecast
12.1.1. By Value
12.2. Market Share & Forecast
12.2.1. By Component (Kits v/s Services)
12.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
12.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
12.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
12.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
12.2.5. By Country
12.3. MEA: Country Analysis
12.3.1. South Africa Hematologic Malignancies Testing Market Outlook
12.3.1.1. Market Size & Forecast
12.3.1.1.1. By Value
12.3.1.2. Market Share & Forecast
12.3.1.2.1. By Component
12.3.1.2.2. By Technique
12.3.1.2.3. By Therapeutic Indication
12.3.1.2.4. By End User
12.3.2. Saudi Arabia Hematologic Malignancies Testing Market Outlook
12.3.2.1. Market Size & Forecast
12.3.2.1.1. By Value
12.3.2.2. Market Share & Forecast
12.3.2.2.1. By Component
12.3.2.2.2. By Technique
12.3.2.2.3. By Therapeutic Indication
12.3.2.2.4. By End User
12.3.3. UAE Hematologic Malignancies Testing Market Outlook
12.3.3.1. Market Size & Forecast
12.3.3.1.1. By Value
12.3.3.2. Market Share & Forecast
12.3.3.2.1. By Component
12.3.3.2.2. By Technique
12.3.3.2.3. By Therapeutic Indication
12.3.3.2.4. By End User
12.3.4. Turkey Hematologic Malignancies Testing Market Outlook
12.3.4.1. Market Size & Forecast
12.3.4.1.1. By Value
12.3.4.2. Market Share & Forecast
12.3.4.2.1. By Component
12.3.4.2.2. By Technique
12.3.4.2.3. By Therapeutic Indication
12.3.4.2.4. By End User
12.3.5. Egypt Hematologic Malignancies Testing Market Outlook
12.3.5.1. Market Size & Forecast
12.3.5.1.1. By Value
12.3.5.2. Market Share & Forecast
12.3.5.2.1. By Component
12.3.5.2.2. By Technique
12.3.5.2.3. By Therapeutic Indication
12.3.5.2.4. By End User
13. Market Dynamics
13.1. Drivers
13.2. Challenges
14. Market Trends & Developments
15. Competitive Landscape
15.1. Abbott Laboratories, Inc.
15.2. Asuragen Inc.
15.3. Bio-Rad Laboratories, Inc.
15.4. Adaptive Biotechnologies Corporation
15.5. F.Hoffmann-La-Roche AG
15.6. Illumina, Inc.
15.7. ICON plc.
15.8. Invitae Corporation
15.9. Laboratory Corporation of America Holdings
15.10. Invivoscribe, Inc.
16. Strategic Recommendations